ISO 35001:2019 - Biorisk Management for Laboratories Foundation Free Practice Test — 30 Questions

Question 1

A research laboratory is tasked with developing a novel vaccine using a genetically modified avian virus. The initial risk assessment identifies a significant potential for aerosolized transmission of the virus during cell culture manipulation. Considering the principles of the hierarchy of controls as mandated by ISO 35001:2019 for effective biorisk management, which sequence of control measures would represent the most robust and preferred strategy for mitigating this identified risk?

Accepted Answer

Prioritize elimination or substitution of the hazardous agent, followed by engineering controls, then administrative controls, and finally personal protective equipment.

Question 2

A biosafety officer at a research facility is developing a comprehensive biorisk management plan for a new project involving the manipulation of a novel, genetically modified virus with unknown pathogenicity characteristics. The laboratory is equipped with Biosafety Level 2 (BSL-2) containment, and the research team has extensive experience with viral vectors. Considering the principles outlined in ISO 35001:2019, which of the following approaches best reflects the necessary steps for establishing an effective biorisk management strategy for this specific scenario?

Accepted Answer

Conduct a detailed hazard identification and risk assessment, including a thorough review of the virus's genetic modifications and potential for aerosolization, followed by the implementation of enhanced containment and procedural controls, and establish a schedule for regular reassessment based on emerging scientific data and operational experience.

Question 3

A research laboratory is preparing to work with a newly synthesized viral vector exhibiting an uncharacterized potential for zoonotic transmission and enhanced environmental persistence. The principal investigator is tasked with establishing a comprehensive biorisk management system for this novel agent. Which of the following actions represents the most critical initial step in ensuring the safety of personnel and the environment, aligning with the principles of ISO 35001:2019?

Accepted Answer

Conduct a thorough hazard identification and risk assessment to determine appropriate containment strategies and control measures.

Question 4

A research laboratory specializing in the manipulation of novel viral vectors has implemented a robust biosafety program aligned with ISO 35001:2019. During a routine internal audit of their containment strategy, the biorisk manager is reviewing the effectiveness of the primary containment measures for aerosol-generating procedures. While no breaches have occurred, the manager wants to ensure the system\'s resilience against unforeseen failures in the containment chain. Which approach best reflects the proactive risk management philosophy mandated by the standard for assessing the integrity of containment controls?

Accepted Answer

Evaluating the potential failure modes of the biosafety cabinet's HEPA filtration system and the integrity of its seals, considering scenarios of degradation or improper installation.

Question 5

A research laboratory is planning to introduce a novel gene-editing technique utilizing a modified lentiviral vector for delivery into primary human cell cultures. Considering the principles outlined in ISO 35001:2019 for establishing and maintaining a biorisk management system, what is the most critical initial step to ensure the safe and secure handling of this new biological agent and associated procedures?

Accepted Answer

Conduct a comprehensive risk assessment to identify and evaluate potential hazards and risks associated with the lentiviral vector and experimental procedures.

Question 6

When initiating the development of a biorisk management system (BRMS) in a newly established research laboratory focused on novel viral vector development, what is the most critical initial step to ensure compliance with national biosafety regulations and international best practices, as stipulated by ISO 35001:2019?

Accepted Answer

Conducting a thorough review of all applicable national and regional biosafety legislation, licensing requirements, and any specific directives from health and environmental protection agencies relevant to the handling of viral vectors.

Question 7

Consider a scenario where a research laboratory is tasked with characterizing a newly identified, highly virulent strain of avian influenza virus with significant airborne transmission potential. The laboratory is operating under ISO 35001:2019 guidelines for biorisk management. Which control strategy, when implemented for handling aerosolized samples of this pathogen, would represent the most robust and preferred approach according to the established hierarchy of controls within the standard?

Accepted Answer

Utilization of Class III biological safety cabinets with rigorous negative pressure monitoring and HEPA filtration for all manipulations.

Question 8

Consider a molecular diagnostics laboratory that has recently introduced a novel assay utilizing a genetically modified virus for viral RNA detection. The laboratory director is reviewing the existing biorisk management system to ensure its alignment with ISO 35001:2019. Which of the following approaches best reflects the standard\'s emphasis on proactive and systematic biorisk mitigation for this new procedure?

Accepted Answer

Implementing a comprehensive risk assessment that evaluates the likelihood and severity of potential exposures to the genetically modified virus during sample handling, reagent preparation, and waste disposal, and then selecting appropriate containment and personal protective equipment based on these findings.

Question 9

A research team at the Pasteur Institute is initiating a new project involving the isolation and characterization of a recently discovered avian influenza virus with unknown pathogenic potential. The laboratory is equipped with standard biosafety cabinets and has established protocols for handling infectious agents. Considering the principles of ISO 35001:2019, what is the most critical initial step to ensure effective biorisk management for this novel research?

Accepted Answer

Conduct a comprehensive risk assessment that identifies potential hazards, evaluates exposure likelihood and severity, and considers all aspects of the new protocol and the biological agent.

Question 10

A research laboratory is conducting experiments with a known BSL-2 pathogen, and a critical step involves manual pipetting of liquid cultures, which has been identified as an aerosol-generating procedure. The risk assessment indicates a moderate likelihood of personnel exposure through inhalation if controls are not adequately implemented. Considering the hierarchy of controls and the specific nature of the pathogen and procedure, which control measure would be the most effective primary intervention to mitigate this identified risk?

Accepted Answer

Utilization of a certified biological safety cabinet for all pipetting activities

Question 11

Consider a scenario at the Biosafety Level 3 (BSL-3) facility of the Pasteur Institute in Paris, where a researcher, Dr. Anya Sharma, notices a small, contained aerosol release from a centrifuge rotor during a high-speed spin of a novel avian influenza strain. The release appears to be localized within the primary containment device itself, but the integrity of the biosafety cabinet (BSC) is not immediately compromised. According to the principles outlined in ISO 35001:2019 for managing biorisks in laboratories, what is the most appropriate immediate course of action to address this incident?

Accepted Answer

Immediately cease the operation, secure the area around the centrifuge, and initiate the laboratory's incident response protocol for containment breaches, including notification of the biosafety officer.

Question 12

A research laboratory working with a genetically modified strain of *Bacillus anthracis* at Biosafety Level 3 (BSL-3) experiences an unexpected aerosolization event during a routine sample preparation procedure. A small quantity of the agent is released within the primary containment device, but the secondary containment (the laboratory itself) is not breached. The laboratory\'s biorisk management system, designed in accordance with ISO 35001:2019, requires a specific sequence of actions following such an incident. Which of the following sequences best reflects the immediate and subsequent steps mandated by a robust biorisk management framework for this scenario?

Accepted Answer

Immediately initiate a full facility lockdown, conduct a detailed root cause analysis of the aerosolization event, decontaminate the primary containment device and surrounding work area, and review and update the relevant Standard Operating Procedures (SOPs) for sample preparation.

Question 13

Following an incident involving the accidental, contained release of a biosafety level 2 (BSL-2) organism within a research laboratory, what is the most crucial subsequent step in adhering to the principles of ISO 35001:2019 for enhancing the overall biorisk management system?

Accepted Answer

A comprehensive revision of the biorisk management system, incorporating lessons learned from the incident investigation and updating risk assessments, control measures, and training protocols.

Question 14

Consider a research laboratory in a country with stringent biosafety regulations, such as those aligned with the European Union\'s directives on the contained use of genetically modified micro-organisms. The laboratory is preparing to work with a newly isolated viral variant exhibiting increased aerosolization potential compared to its wild-type progenitor. The existing biosafety level (BSL) designation for the wild-type virus is BSL-2. Which of the following actions most critically reflects a proactive and compliant approach to managing the biorisk associated with this new variant, in accordance with the principles of ISO 35001:2019?

Accepted Answer

Conducting a comprehensive reassessment of the biorisk, considering the variant's specific properties, the proposed experimental procedures, and the adequacy of existing containment and control measures to determine the appropriate biosafety level and necessary enhancements.

Question 15

A research laboratory working with genetically modified microorganisms has experienced three separate minor containment breaches involving a specific biosafety level 2 (BSL-2) agent during routine cell culture manipulations that generate aerosols. Internal incident reports and subsequent investigations have pinpointed inconsistencies in the adherence to established standard operating procedures (SOPs) for these specific procedures, as well as potential limitations in the current ventilation system of the primary containment area. Considering the principles of continual improvement within a biorisk management framework as defined by ISO 35001:2019, which of the following actions would most effectively demonstrate the laboratory\'s commitment to enhancing its biorisk management system in response to these events?

Accepted Answer

Revise the relevant SOPs to incorporate more explicit instructions for aerosol-generating procedures, retrain all personnel on the updated protocols, and initiate a review of the ventilation system's performance to determine if upgrades are necessary.

Question 16

A biosafety committee at a research institution is reviewing its biorisk management program following an incident involving a near-miss with a Category 3 pathogen. The committee is tasked with ensuring the laboratory\'s practices are not only compliant with national biosafety regulations but also fully aligned with the principles of ISO 35001:2019. Which of the following actions would best demonstrate a mature and integrated approach to biorisk management, moving beyond basic compliance to proactive risk mitigation?

Accepted Answer

Conducting a comprehensive reassessment of all identified biorisks, evaluating the effectiveness of existing control measures against current operational procedures and regulatory requirements, and documenting any necessary adjustments to the control hierarchy.

Question 17

A high-containment research laboratory is undergoing its annual biorisk management review. The laboratory handles several Biosafety Level 3 (BSL-3) agents, including *Mycobacterium tuberculosis* and *Brucella abortus*. The current risk assessment documentation details the identified hazards associated with these agents and the standard operating procedures (SOPs) for their manipulation. However, the review team notes that the assessment has not explicitly evaluated the effectiveness of the existing engineering controls (e.g., biosafety cabinets, negative pressure rooms) in the context of recent minor power fluctuations experienced by the facility, nor has it quantified the impact of a newly implemented automated liquid handling system on potential aerosol generation during sample processing. Furthermore, the assessment does not detail the process for reassessing risks following any significant changes to procedures or equipment, as stipulated by the standard\'s iterative nature. Which of the following actions is most critical to ensure the laboratory\'s biorisk management system remains compliant with ISO 35001:2019 principles?

Accepted Answer

Conduct a thorough re-evaluation of all identified biorisks, specifically assessing the performance of engineering controls under varied operational conditions and quantifying the impact of new technologies on potential exposure pathways.

Question 18

A research laboratory operating under BSL-2 conditions experiences an accidental release of a bacterial culture during a routine transfer procedure. The spill is contained promptly with minimal exposure risk, but the incident highlights a potential gap in the current handling protocols for liquid cultures. According to the principles of ISO 35001:2019 for biorisk management, what is the most critical subsequent step to ensure continuous improvement of the laboratory\'s safety system?

Accepted Answer

Initiate a comprehensive review of the specific spill containment procedures and associated personnel training for liquid culture transfers.

Question 19

When establishing a biorisk management system in accordance with ISO 35001:2019, what fundamental step is required to ensure the system\'s relevance and effectiveness within its operating environment?

Accepted Answer

Comprehensive identification and analysis of internal and external factors, including legal and regulatory requirements and stakeholder needs, to define the system's scope and context.

Question 20

When establishing a comprehensive biorisk management system within a high-containment virology laboratory, what is the most critical foundational step to ensure the subsequent implementation of effective and proportionate control measures, aligning with the principles of ISO 35001:2019?

Accepted Answer

Conducting a systematic identification and assessment of all potential biorisks, considering agents, procedures, equipment, and the laboratory environment.

Question 21

A research laboratory, accredited under ISO 35001:2019, is planning to work with a newly identified viral agent exhibiting high transmissibility and potential for severe human health impacts. Prior to commencing any experimental work, what is the most critical initial step that the laboratory must undertake to ensure compliance with the standard and effective biorisk management?

Accepted Answer

Conduct a comprehensive risk assessment to identify potential hazards, evaluate associated risks, and determine appropriate control measures, including the selection of suitable biosafety levels and engineering controls.

Question 22

When establishing a biorisk management system in accordance with ISO 35001:2019, which foundational element is paramount for ensuring the system\'s relevance and effectiveness, encompassing the identification of external and internal factors that could impact the organization\'s ability to manage biological risks and the needs of all pertinent stakeholders?

Accepted Answer

Thoroughly defining the organizational context and identifying all relevant interested parties and their specific requirements.

Question 23

A research laboratory is developing a novel gene therapy vector using a modified lentivirus. During the risk assessment phase, the team identifies potential aerosol generation during cell culture harvesting and accidental sharps injuries during sample preparation as primary hazards. Considering the principles outlined in ISO 35001:2019 for managing biorisks in laboratories, which of the following best describes the subsequent critical step in the risk assessment process for these identified hazards?

Accepted Answer

Characterizing the identified hazards and estimating the likelihood and severity of potential harm to determine the risk level.

Question 24

Consider a high-containment laboratory working with novel airborne pathogens. A recent internal audit identified a potential for aerosol generation during a specific sample preparation step, a scenario not yet documented as an incident. Which of the following actions best exemplifies the proactive biorisk management principles mandated by ISO 35001:2019 in addressing this identified, but unmanifested, risk?

Accepted Answer

Implementing enhanced ventilation controls and mandatory use of specialized respiratory protection for all personnel involved in that specific sample preparation step.

Question 25

A research laboratory specializing in novel viral vector development is undergoing its annual biorisk management review. The team has compiled a comprehensive list of potential hazards, ranging from aerosol generation during centrifugation to accidental exposure to genetically modified organisms. They have also documented past near-misses and minor incidents. To effectively move from hazard identification to actionable control measures, what is the most critical next step according to the principles of ISO 35001:2019?

Accepted Answer

Systematically evaluate the identified hazards based on their likelihood of occurrence and the potential severity of their consequences to determine the level of risk.

Question 26

When establishing a biorisk management system in a high-containment research laboratory, what is the most critical initial step to ensure the system\'s relevance and effectiveness, considering both internal capabilities and external regulatory frameworks such as those potentially influenced by the Select Agent Regulations in the United States or similar national biosafety legislation?

Accepted Answer

Conducting a thorough analysis of the laboratory's operational context, including its specific biological agents, research activities, physical infrastructure, personnel competencies, and all applicable legal and regulatory requirements.

Question 27

A research laboratory is preparing to work with a newly synthesized viral vector designed for gene therapy applications. This vector, while showing promise, has not been extensively characterized regarding its potential for aerosolization, its interaction with human cell lines beyond the intended target, or its environmental persistence. The laboratory has existing protocols for handling Biosafety Level 2 (BSL-2) agents. Which of the following actions represents the most critical initial step in establishing a robust biorisk management framework for this novel agent, in accordance with ISO 35001:2019 principles?

Accepted Answer

Conduct a thorough risk assessment to determine the appropriate biosafety level and necessary control measures for the novel viral vector.

Question 28

Consider a research laboratory in a country with stringent biosafety regulations, such as those mirroring the principles of the European Union\'s Directive 2000/54/EC on the protection of workers from risks related to exposure to biological agents at work. The laboratory is commencing a new project involving the manipulation of a novel strain of highly pathogenic avian influenza (HPAI). What is the most effective initial step in establishing a robust biorisk management plan for this specific project, in accordance with ISO 35001:2019 principles?

Accepted Answer

Conduct a comprehensive hazard identification and risk assessment specific to the HPAI strain and all proposed laboratory procedures.

Question 29

When initiating the development of a comprehensive biorisk management system compliant with ISO 35001:2019, what is the critical prerequisite for defining operational controls and emergency preparedness measures?

Accepted Answer

A thorough analysis of the organization's internal and external context, coupled with the identification of all relevant interested parties and their specific requirements.

Question 30

Consider a high-containment laboratory tasked with characterizing a newly isolated avian influenza virus exhibiting unusually high aerosol transmission efficiency in preliminary animal models. The laboratory\'s biorisk management system, aligned with ISO 35001:2019 principles, is undergoing its annual review. Which of the following approaches best reflects the foundational requirement for identifying and evaluating the potential hazards associated with this specific agent and its handling within the laboratory environment?

Accepted Answer

Primarily focusing on the documented biosafety level (BSL) of the virus based on existing literature and implementing standard containment protocols for that BSL.

ISO 35001:2019 - Biorisk Management for Laboratories Foundation Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 35001:2019 - Biorisk Management for Laboratories Foundation Certification